Acuta Capital Partners, LLC Stoke Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$30.53 - $41.09 $1.37 Million - $1.85 Million	-45,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$36.08 - $69.81 $1.71 Million - $3.32 Million	-47,500 Reduced 51.35%	45,000 $1.75 Million
Q4 2020 Feb 16, 2021	BUY	$33.62 - $61.93 $3.11 Million - $5.73 Million	92,500 New	92,500 $5.73 Million

123

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $446M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.